APA (7th ed.) Citation

DKA, C., R, S., G, K., JJ, A., JHY, L., ME, N., . . . WP, Y. (2022). Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals of surgical oncology, 29(13), 8597. https://doi.org/10.1245/s10434-022-11998-z

Chicago Style (17th ed.) Citation

DKA, Chia, et al. "Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases." Annals of Surgical Oncology 29, no. 13 (2022): 8597. https://doi.org/10.1245/s10434-022-11998-z.

MLA (9th ed.) Citation

DKA, Chia, et al. "Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases." Annals of Surgical Oncology, vol. 29, no. 13, 2022, p. 8597, https://doi.org/10.1245/s10434-022-11998-z.